AtaiBeckley Inc. (NASDAQ:ATAI) earns a place on our list of the top 10 stocks under $5 that could triple. Analysts are ...
AtaiBeckley (NasdaqGM:ATAI) reported positive, peer reviewed Phase 2a results for its lead psychedelic drug BPL-003 in treatment resistant depression. The company received supportive FDA feedback for ...
NEW YORK and BERLIN and OXFORD, United Kingdom, June 02, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company on a mission to ...
AtaiBeckley Inc (NASDAQ:ATAI) is among the best psychedelic stocks to buy in 2026. On March 17, AtaiBeckley Inc (NASDAQ:ATAI) ...
NEW YORK, and AMSTERDAM and OXFORD, United Kingdom, July 01, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company on a mission to develop ...
ELE-101 is a patent-protected, synthetic formulation of psilocin, designed to offer the therapeutic benefits of psilocybin in a more consistent, controllable, and shorter treatment paradigm of ...
AtaiBeckley Inc. (NASDAQ:ATAI) is one of the Best Penny Stocks That Will Skyrocket. Wall Street is bullish on AtaiBeckley Inc. (NASDAQ:ATAI) with analysts’ 12-month median price target reflecting more ...
That drug, tagged BPL-003 by Atai, is an antidepressant that was recently evaluated in an open-label phase 2a study. The company is developing the medication in collaboration with a privately held ...
Atai Life Sciences (NASDAQ:ATAI) and Beckley Psytech Limited, a private clinical-stage biopharmaceutical company, released data from a proof-of-concept study investigating a two-dose induction regimen ...
Atai Beckley NV (NASDAQ:ATAI) ranks among the most oversold biotech stocks to invest in. H.C. Wainwright reaffirmed its Buy rating and $15 price target for Atai Beckley NV (NASDAQ:ATAI) on November 14 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results